Q1 2026 Cigna Group Earnings Call Transcript
Key Points
- The Cigna Group (CI) reported strong first-quarter performance with total revenues of $68.5 billion and adjusted earnings per share of $7.79.
- The company raised its full-year 2026 adjusted EPS outlook to at least $30.35, reflecting confidence in sustained growth and disciplined execution.
- Cigna's Specialty and Care Services businesses showed strong growth, with adjusted earnings up 20% in the quarter, driven by increased biosimilar and specialty generic adoption.
- The introduction of the rebate-free pharmacy service model, Signature, is expected to deliver the lowest price to consumers for brand drugs, enhancing affordability and transparency.
- Cigna Healthcare was ranked number one by J.D. Power in digital experience satisfaction among commercial health plan members for the second consecutive year, highlighting strong consumer engagement.
- The company recorded after-tax special items charges of $322 million or $1.22 per share in the first quarter.
- Cigna is planning to exit its individual exchange business at the end of the year, indicating challenges in scaling this segment.
- The Pharmacy Benefit Services segment saw a 28% decrease in pretax adjusted earnings, attributed to large client renewals and investments in the new Signature model.
- The decision to initiate a strategic review of alternatives for EviCore reflects uncertainties in the standardization and automation of prior authorization services.
- The ongoing tension between affordability and employee demand for GLP-1 drugs presents a challenge, as employers balance cost with employee satisfaction.
Ladies and gentlemen, thank you for standing by for the Cigna Group's first-quarter 2026 results review. (Operator Instructions) As a reminder, ladies and gentlemen, this conference, including the Q&A session, is being recorded.
We'll begin by turning the conference over to Ralph Giacobbe. Please go ahead.
Great. Thanks. Good morning, everyone. Thanks for joining today's call. I'm Ralph Giacobbe, Senior Vice President of Investor Relations. With me on the line this morning are David Cordani, the Cigna Group's Chairman and Chief Executive Officer; Brian Evanko, President and Chief Operating Officer; and Ann Dennison, Chief Financial Officer.
In our remarks today, David, Brian and Ann will cover a number of topics, including our first-quarter 2026 financial results and our financial outlook for 2026. Following their prepared remarks, David, Brian and Ann will be available for Q&A. As noted in our earnings release, when describing our financial results, we use
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
